EPIC Program Annual Data Tables 2006-2007: Table VII
Therapeutic Class** | Number of Claims |
Percent of Claims |
EPIC Payments |
Number of Participants |
---|---|---|---|---|
Total*** | 5,272,023 | 46.90% | $336,258,835 | |
BETA-ADRENERGIC BLOCKING AGENT | 1,205,499 | 10.73% | $38,890,866 | 164,503 |
HMG-COA REDUCTASE INHIBITORS | 729,540 | 6.49% | $75,486,343 | 154,665 |
DIHYDROPYRIDINES | 574,510 | 5.11% | $36,045,499 | 77,961 |
ANGIOTENSIN-CONVERTING ENZYME | 536,630 | 4.78% | $14,533,035 | 105,144 |
PROTON-PUMP INHIBITORS | 434,323 | 3.86% | $65,380,312 | 100,689 |
ANTIDEPRESSANTS | 399,759 | 3.56% | $22,355,978 | 72,297 |
ANGIOTENSIN II RECEPTOR ANTAGO | 387,127 | 3.44% | $26,305,827 | 79,255 |
PLATELET-AGGREGATION INHIBITOR | 339,347 | 3.02% | $42,192,824 | 40,749 |
OPIATE AGONISTS | 336,804 | 2.99% | $11,433,522 | 89,201 |
THYROID AGENTS | 328,484 | 2.92% | $3,634,629 | 62,932 |
* Table VII provides the percent of adjudicated claims for the program year (October 1, 2006 through September 30, 2007) as they fall into particular categories of Therapeutic Class.
** American Hospital Formulary Service® (AHFS) Pharmacologic-Therapeutic Classification.
*** This report contains the top ten drug classes; additional drug classes comprise the remainder of claims up to 100.00%.